Navigation Links
OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
Date:12/10/2007

ATLANTA Oregon Health & Science University Cancer Institute researcher Jeff Tyner, Ph.D., has created a way to identify proteins that are candidates for targeted therapy in acute myeloid leukemia using an assay that yields results in just four days. This research will be presented at the American Society of Hematology annual meeting in Atlanta, on Monday, Dec. 10, at 8:15 a.m.

This functional assay, called RAPID, because it rapidly delivers the information, has the capability of telling researchers which actual proteins from the tyrosine kinase family are contributing to an individual patients cancer.

If you know what protein is driving the cancer, you have the ability to target that protein and stop it. With this knowledge it may be possible to match targeted drugs with the appropriate patient. It may also be possible to identify mechanisms as to why certain leukemias respond well to therapy and why others may not. The real novelty of our work is that we have performed this assay directly on patient samples. It gets us one step closer to the clinic and personalized medicine, said Tyner, a fellow in hematology/ medical oncology, OHSU School of Medicine.

This research has several important aspects. First, it will enable researches to more quickly compile a database of mutant genes that cause cancer. That will enable better diagnosis in the future using DNA sequencing technology. Second, it is possible that this technology may, in the future, be adapted for direct clinical use for diagnostic purposes. In this manner, the RAPID screen could be run on a patients malignant cells, and the appropriate drug could then be determined to treat that patient. Thirdly, the assay can be completed in just four days, whereas previous technologies could take months to years to yield similar information.

Tyner came about his discovery as many scientists do: trial and error and then success.

We were initially screening for these targets by doing large-scale DNA sequencing, looking for mutations. This strategy was not as successful as we had hoped, so we decided that an assay that could functionally screen cells and give us some idea based on what killed cells and what didnt kill cells would be a better place to start. We could then work backward to find the actual mutation underlying that phenotype. RNAi (the name of the technology we use) seemed an ideal platform for this because it allows you to knock down the expression of individual genes, Tyner said.


'/>"/>

Contact: Christine Decker
deckerch@ohsu.edu
503-494-8231
Oregon Health & Science University
Source:Eurekalert

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Melbourne’s reign ... by the prestigious Economist Intelligence Unit’s (EIU) annual Liveability Index. , The Index surveys ... Since the index began in 2006, Melbourne has consistently come in the top three ...
(Date:8/16/2017)... ... August 16, 2017 , ... Richard Strawn’s new book ... time of a cancer diagnosis, surgery and recovery, the Psalms provided encouragement and ... ways God shows love to those who are sick., Surgical Psalms contains 36 ...
(Date:8/16/2017)... ... August 16, 2017 , ... Kaviva , a health ... the healthcare market, with Los Angeles-based AIDS Healthcare Foundation ( AHF ), to ... AHF cares for nearly 800,000 individuals worldwide and is the largest HIV/AIDS organization ...
(Date:8/16/2017)... Lewisville, TX (PRWEB) , ... August 16, 2017 , ... ... in the United States, named Dr. Douglas J. Harrison, as the new Medical Director ... will be the new facility Medical Director of our Sienna Plantation location,” said Dr. ...
(Date:8/16/2017)... Ohio (PRWEB) , ... August 16, 2017 , ... ... are an annual all-encompassing awards program which recognizes organizations that demonstrate the core ... set of comprehensive award categories. , “As a global company, we are expanding ...
Breaking Medicine News(10 mins):
(Date:7/31/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO), has been named one of ... by Crain,s Detroit Business . The annual Crain,s ... revenue growth. This year,s edition measures growth from 2013 to ... complete list, visit crainsdetroit.com/awards/fast_50/2017 .  "Being ... Phil Hagerman , CEO and chairman of Diplomat. "We,ve ...
(Date:7/27/2017)... 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... June 30, 2017.  The Company reported second quarter net ... the prior year period, and an increase of 2.1% ... points of contribution from the LDR Holding Corporation acquisition, ... quarter of 2016, or 0.3% on a constant currency ...
(Date:7/26/2017)... The Galien Foundation announced today the ... Award Nominees. Counted among the global health innovation ... biomedical and technology product achievement that improves the human condition. ... candidate must be U.S. Food and Drug Administration (FDA) approved ... potential to impact human health. Sales data are not considered ...
Breaking Medicine Technology: